Clinical Trials
117 trialsNovel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
GlaxoSmithKline
EVEREST-2
A2 Biotherapeutics Inc.
DREAMM-20
GlaxoSmithKline
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
ACTengine
Immatics US, Inc.
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
Lumi-NHL
AstraZeneca
MAPtivate-6
Pfizer
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Regeneron Pharmaceuticals
STOMP
Karyopharm Therapeutics Inc
iMATRIX GLO
Hoffmann-La Roche
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
TITANium
AstraZeneca
LINKER-AL2
Regeneron Pharmaceuticals
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
M.D. Anderson Cancer Center
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
LINKER-MM1
Regeneron Pharmaceuticals
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
PEEL-224
Children's Hospital of Philadelphia
LUPARPED
Fundación de investigación HM
ADAPT-HEM
Beijing Biotech
ZUMA-4
Gilead Sciences
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Autolus Limited
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
FUMANBA-04
Nanjing IASO Biotechnology Co., Ltd.
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Daiichi Sankyo
EpiRev-NKT
Fudan University
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
DUAL-NK-NB
Beijing Biotech
STARTRK-NG
Hoffmann-La Roche
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
DART-NK-SCLC
Beijing Biotech
DUAL-OV-CAR-NK
Beijing Biotech
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC